Department of Radiation Oncology, Rhode Island Hospital, Brown University Warren Alpert Medical School, Providence, Rhode Island; Department of Radiation Oncology, Perlmutter Cancer Center, NYU School of Medicine, New York, New York.
Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina; Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):246-253. doi: 10.1016/j.ijrobp.2016.09.043. Epub 2016 Oct 1.
Optimal patient selection for stereotactic radiosurgery (SRS) as the initial treatment for brain metastases is complicated and controversial. This study aimed to develop a nomogram that predicts survival without salvage whole brain radiation therapy (WBRT) after upfront SRS.
Multi-institutional data were analyzed from 895 patients with 2095 lesions treated with SRS without prior or planned WBRT. Cox proportional hazards regression model was used to identify independent pre-SRS predictors of WBRT-free survival, which were integrated to build a nomogram that was subjected to bootstrap validation.
Median WBRT-free survival was 8 months (range, 0.1-139 months). Significant independent predictors for inferior WBRT-free survival were age (hazard ratio [HR] 1.1 for each 10-year increase), HER2(-) breast cancer (HR 1.6 relative to other histologic features), colorectal cancer (HR 1.4 relative to other histologic features), increasing number of brain metastases (HR 1.09, 1.32, 1.37, and 1.87 for 2, 3, 4, and 5+ lesions, respectively), presence of neurologic symptoms (HR 1.26), progressive systemic disease (HR 1.35), and increasing extracranial disease burden (HR 1.31 for oligometastatic and HR 1.56 for widespread). Additionally, HER2(+) breast cancer (HR 0.81) and melanoma (HR 1.11) trended toward significance. The independently weighted hazard ratios were used to create a nomogram to display estimated probabilities of 6-month and 12-month WBRT-free survival with a corrected Harrell's C concordance statistic of 0.62.
Our nomogram can be used at initial evaluation to help select patients best suited for upfront SRS for brain metastases while reducing expense and morbidity in patients who derive minimal or no benefit.
对于立体定向放射外科(SRS)作为脑转移初始治疗的最佳患者选择较为复杂且存在争议。本研究旨在开发一种列线图,预测初始 SRS 后无需挽救性全脑放疗(WBRT)的生存情况。
分析了 895 例 2095 个病灶接受 SRS 治疗且未行 WBRT 或无计划行 WBRT 的多机构数据。采用 Cox 比例风险回归模型识别独立的 SRS 前预测 WBRT 无进展生存的因素,这些因素被整合到一个列线图中,并进行了 bootstrap 验证。
中位 WBRT 无进展生存期为 8 个月(范围,0.1-139 个月)。较差的 WBRT 无进展生存的显著独立预测因素包括年龄(每增加 10 岁,风险比 [HR] 为 1.1)、HER2(-)乳腺癌(与其他组织学特征相比,HR 为 1.6)、结直肠癌(与其他组织学特征相比,HR 为 1.4)、脑转移灶数量增加(HR 分别为 1.09、1.32、1.37 和 1.87,用于 2、3、4 和 5 个以上病灶)、存在神经系统症状(HR 1.26)、进展性全身性疾病(HR 1.35)和远处转移灶数量增加(HR 1.31,用于寡转移,HR 1.56,用于广泛转移)。此外,HER2(+)乳腺癌(HR 0.81)和黑色素瘤(HR 1.11)呈显著趋势。使用独立加权风险比创建了一个列线图,以显示 6 个月和 12 个月 WBRT 无进展生存的估计概率,校正后的 Harrell's C 一致性指数为 0.62。
我们的列线图可在初始评估时使用,有助于选择最适合初始 SRS 治疗脑转移的患者,同时减少在获益最小或无获益的患者中进行 WBRT 的费用和发病率。